Bacillus Calmette-Guerin (BCG) Vaccine Market
The Bacillus Calmette-Guérin (BCG) vaccine market, a global market for a vaccine against tuberculosis (TB), is estimated to reach $210 million by 2030, with the BCG vaccine being the only available vaccine for TB prevention.
The BCG vaccine, developed by Albert Calmette and Camille Guerin, is a live attenuated vaccine derived from a strain of Mycobacterium bovis (a bacterium related to Mycobacterium tuberculosis, the cause of TB).